PDEA's Ayurveda Rugnalaya & Sterling Multi Speciality Hospital

Near, Sant Dyaneshwar Chowk, Sector No. 27, Pradhikaran, Nigdi, Pimpri-Chinchwad, Maharashtra 411044

PI ; Dr Rakesh Neve ( Surgical Oncologist )

Below Mentioned Study Ongoing .

1. “A Phase 2a, Multi-center, Open Label, Dose Optimization, Pilot Study to Assess the Safety and Tolerability at the Maximum Tolerated Dose of Parenteral TK-112690 in Non- Metastatic Squamous CellCarcinoma of Head and Neck Patients Scheduled to Receive Chemoradiation.”

2. A multi-center, open-label, balanced, randomized, two-treatment, two-period, twosequence,two-way crossover, multiple-dose, steady-state bioequivalence study of Pazopanib HCl Tablets 200mg (4 Tablets X 200 mg) of MSN Laboratories Private Limited, India compared with Votrient® Tablet200mg (4 Tablets X 200 mg) of Novartis Pharmaceuticals Corporation, USA in Advanced renal cellcarcinoma patients who are already receiving Pazopanib HCl tablets in standard therapy, and who are tolerating a stable dosing regimen of 800 mg/day under fasting conditions.

3. A Multicenter, Double-Blind, Randomized, Parallel-Group, Active-Controlled, Phase III, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BP02 (Trastuzumab) in comparison with Herceptin®-EU in Patients with HER2-Positive Metastatic Breast Cancer (MBC)